The State of Intermediate Clinical Endpoints as Surrogates for Overall Survival in Prostate Cancer in 2024.
In the past, selection of intermediate clinical endpoints (ICEs) in prostate cancer (PCa) trials largely depended on qualitative assessments; however, the advancing quality of research necessitates a robust correlation with overall survival (OS). This …